Samsudin Ely Zarina, Kamarul Tunku
Clinical Investigation Centre, University Malaya Medical Centre, 59100, Kuala Lumpur, Malaysia.
Knee Surg Sports Traumatol Arthrosc. 2016 Dec;24(12):3912-3926. doi: 10.1007/s00167-015-3649-x. Epub 2015 May 24.
This paper aims to review the current evidence for autologous chondrocyte implantation (ACI) generations relative to other treatment modalities, different cell delivery methods and different cell source application.
Literature search was performed to identify all level I and II studies reporting the clinical and structural outcome of any ACI generation in human knees using the following medical electronic databases: PubMed, EMBASE, Cochrane Library, CINAHL, SPORTDiscus and NICE healthcare database. The level of evidence, sample size calculation and risk of bias were determined for all included studies to enable quality assessment.
Twenty studies were included in the analysis, reporting on a total of 1094 patients. Of the 20 studies, 13 compared ACI with other treatment modalities, seven compared different ACI cell delivery methods, and one compared different cell source for implantation. Studies included were heterogeneous in baseline design, preventing meta-analysis. Data showed a trend towards similar outcomes when comparing ACI generations with other repair techniques and when comparing different cell delivery methods and cell source selection. Majority of the studies (80 %) were level II evidence, and overall the quality of studies can be rated as average to low, with the absence of power analysis in 65 % studies.
At present, there are insufficient data to conclude any superiority of ACI techniques. Considering its two-stage operation and cost, it may be appropriate to reserve ACI for patients with larger defects or those who have had inadequate response to other repair procedures until hard evidence enables specific clinical recommendations be made.
II.
本文旨在综述与其他治疗方式、不同细胞递送方法及不同细胞来源应用相关的自体软骨细胞移植(ACI)各代技术的现有证据。
通过文献检索,利用以下医学电子数据库确定所有报告人类膝关节任何一代ACI技术临床和结构结果的I级和II级研究:PubMed、EMBASE、Cochrane图书馆、CINAHL、SPORTDiscus和NICE医疗保健数据库。确定所有纳入研究的证据水平、样本量计算和偏倚风险,以进行质量评估。
分析纳入了20项研究,共报告了1094例患者。在这20项研究中,13项比较了ACI与其他治疗方式,7项比较了不同的ACI细胞递送方法,1项比较了不同的植入细胞来源。纳入的研究在基线设计上存在异质性,无法进行荟萃分析。数据显示,在比较ACI各代技术与其他修复技术时,以及在比较不同细胞递送方法和细胞来源选择时,结果有相似趋势。大多数研究(80%)为II级证据,总体而言,研究质量可评为中等至低等,65%的研究未进行功效分析。
目前,尚无足够数据得出ACI技术具有任何优越性的结论。考虑到其两阶段手术和成本,对于缺损较大或对其他修复程序反应不佳的患者,在有确凿证据支持做出具体临床建议之前,保留ACI技术可能是合适的。
II级